Hims & Hers Health Surges 5.21% in Trading Volume Ranking 26th with $24 Billion

On June 20, 2025, Hims & Hers Health (HIMS) saw a trading volume of $24.00 billion, ranking 26th in the day's stock market activity. The stock experienced a 5.21% increase, marking its second consecutive day of gains, with a total rise of 8.46% over the past two days.

Hims & Hers Health operates a telehealth platform that connects consumers with licensed healthcare professionals across the United States, the United Kingdom, and other international markets. The company offers a range of health and wellness products and services, including prescription and non-prescription items, which are available for purchase directly through their websites and mobile applications. Additionally, Hims & Hers provides recurring prescription medication and ongoing care from healthcare providers, as well as over-the-counter drugs, devices, cosmetics, and supplements.

Hims & Hers Health has reported significant growth in its subscriber base, with 2.4 million subscribers in Q1 FY25, representing a 38% year-over-year increase from 1.74 million in Q1 FY24. Personalized treatments now account for 58% of the subscriber base, with 70% of new users opting for these services. This growth is driven by the increasing adoption of the company's personalized healthcare offerings, which have shown strong user and revenue growth.

One of the key developments for Hims & Hers Health is its acquisition of ZAVA, a European digital health platform. This acquisition allows Hims & Hers to expand its services into Germany, France, and Ireland, significantly increasing its active customer base by approximately 54%. The deal is expected to accelerate the company's growth in Europe's weight-loss market, leveraging ZAVA's established presence and customer base.

Hims & Hers Health has also introduced a 6-month Wegovy® new customer offer, providing eligible customers with access to the prescription-only weight-loss drug at an affordable price. This initiative aims to capitalize on the growing demand for weight-loss solutions and further solidify the company's position in the market.

Despite the positive developments, Hims & Hers Health has faced challenges, including a 4% reduction in its workforce due to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. This adjustment reflects the company's efforts to adapt to regulatory changes and maintain operational efficiency.